Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Prostatic Neoplasms 22Breast Neoplasms 21Polycystic Ovary Syndrome 12Carcinoma, Non-Small-Cell Lung 11Colorectal Neoplasms 10Lung Neoplasms 8Endometrial Neoplasms 7Pancreatic Neoplasms 6Neoplasms 6Glioblastoma 5Rectal Neoplasms 4Melanoma 4Lymphoma, Large B-Cell, Diffuse 4Insulin Resistance 4Adenocarcinoma of Lung 4Adenocarcinoma 4Uterine Cervical Neoplasms 3Leukoplakia, Oral 3Urinary Bladder Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Obesity 2Neoplasm Metastasis 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Hyperandrogenism 2Esophageal Neoplasms 2Erythroplasia 2Endometrial Hyperplasia 2Diabetes Mellitus 2Colonic Neoplasms 2

Interventions

Epoetin Alfa 2Cyclophosphamide 2tanespimycin 1piperine 1isatuximab 1fludarabine phosphate 1aldesleukin 1Therapeutics 1Rituximab 1Radiotherapy 1Peripheral Blood Stem Cell Transplantation 1Metformin 1Interferon-alpha 1Gene Expression Profiling 1Fatty Acids, Omega-3 1Darbepoetin alfa 1Curcumin 1Celecoxib 1Caspofungin 1Antilymphocyte Serum 1AH 111585 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Monoclonal Gammopathy of Undetermined Significance × Metformin × Clear all
NCT04850846 2026-02-09

Investigation of Metformin for the Prevention of Progression of Precursor Multiple Myeloma

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
60 enrolled 10 charts
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance

Data powered by HemOnc (CC BY 4.0) Colophon âš¡